Entropy Technologies LP acquired a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) in the 1st quarter, Holdings Channel.com reports. The fund acquired 29,470 shares of the conglomerate’s stock, valued at approximately $5,588,000.
Other hedge funds have also recently modified their holdings of the company. Main Street Group LTD bought a new position in shares of Danaher in the 1st quarter worth about $25,000. JPL Wealth Management LLC bought a new stake in Danaher during the third quarter worth about $25,000. Elevated Capital Advisors LLC bought a new stake in Danaher during the fourth quarter worth about $26,000. WFA of San Diego LLC purchased a new stake in Danaher in the second quarter worth about $26,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in Danaher in the fourth quarter worth about $27,000. Institutional investors own 79.05% of the company’s stock.
Danaher Stock Down 0.3%
DHR stock opened at $191.87 on Friday. The stock has a market capitalization of $134.88 billion, a P/E ratio of 34.08, a P/E/G ratio of 2.38 and a beta of 0.79. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.52. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The business has a fifty day moving average price of $185.64 and a 200-day moving average price of $197.04.
Danaher Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.
Trending Headlines about Danaher
Here are the key news stories impacting Danaher this week:
- Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
- Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
- Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
- Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
- Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on DHR. Wells Fargo & Company lowered their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday. Evercore restated an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. DZ Bank initiated coverage on Danaher in a research report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price objective for the company. Morgan Stanley lowered their price objective on Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. Finally, Guggenheim dropped their target price on Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $228.91.
Get Our Latest Stock Analysis on DHR
About Danaher
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
See Also
- Five stocks we like better than Danaher
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
